Nice_老虎社区_美港股上老虎

来人
2021-10-25

Nice

Sanofi/Regeneron: more positive Phase 3 trial results for Dupixent<blockquote>赛诺菲/再生元：Dupixent更积极的3期试验结果</blockquote>

Sanofi /Regeneron :Second Dupixent® (Dupilumab) Phase 3 Eosinophilic Esophagitis Trial To Demonstrat

Sanofi/Regeneron: more positive Phase 3 trial results for Dupixent<blockquote>赛诺菲/再生元：Dupixent更积极的3期试验结果</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":856189930,"tweetId":"856189930","gmtCreate":1635160921196,"gmtModify":1635160921196,"author":{"id":3575544575320394,"idStr":"3575544575320394","authorId":3575544575320394,"authorIdStr":"3575544575320394","name":"来人","avatar":"https://static.tigerbbs.com/0af89587decbb8a1d3e1596adc29cb98","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":68,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Nice</p></body></html>","htmlText":"<html><head></head><body><p>Nice</p></body></html>","text":"Nice","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/856189930","repostId":2178442079,"repostType":2,"repost":{"id":"2178442079","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1635138271,"share":"https://www.laohu8.com/m/news/2178442079?lang=zh_CN&edition=full","pubTime":"2021-10-25 13:04","market":"hk","language":"en","title":"Sanofi/Regeneron: more positive Phase 3 trial results for Dupixent<blockquote>赛诺菲/再生元：Dupixent更积极的3期试验结果</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2178442079","media":"T-Reuters","summary":"Sanofi /Regeneron :Second Dupixent® (Dupilumab) Phase 3 Eosinophilic Esophagitis Trial To Demonstrat","content":"<p><html><body><a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> <sasy.pa>/Regeneron <regn.o>:Second Dupixent® (Dupilumab) Phase 3 Eosinophilic Esophagitis Trial To Demonstrate Significant Disease Improvements, Underscoring Role Of Type 2 Inflammation In This Complex Disease.Phase 3 Eosinophilic Esophagitis Trial To Demonstrate Significant Disease Improvements.Data Continue To Support Well-Established Safety Profile Of Dupixent.Encouraged That Dupixent, Which Targets Il-4 And Il-13, Was Able To Reduce Inflammation In Esophagus.Look Forward To Continuing Studying Dupixent'S Potential Role In Addressing Underlying Type 2 Inflammation That Can Lead To Eosinophilic Esophagitis.</regn.o></sasy.pa></p><p><blockquote><html><body><a href=\"https://laohu8.com/S/GCVRZ\">赛诺菲</a><sasy.pa>/再生元<regn.o>：第二个Dupixent®（Dupilumab）3期嗜酸性食管炎试验证明了显著的疾病改善，强调了2型炎症在这种复杂疾病中的作用。3期嗜酸性食管炎试验证明疾病有显著改善。数据继续支持Dupixent的良好安全性。令人鼓舞的是，靶向Il-4和Il-13的Dupixent能够减少食道炎症。期待继续研究Dupixent在解决可能导致嗜酸性食管炎的潜在2型炎症方面的潜在作用。</regn.o></sasy.pa></body></html></blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi/Regeneron: more positive Phase 3 trial results for Dupixent<blockquote>赛诺菲/再生元：Dupixent更积极的3期试验结果</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi/Regeneron: more positive Phase 3 trial results for Dupixent<blockquote>赛诺菲/再生元：Dupixent更积极的3期试验结果</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time smaller\">2021-10-25 13:04</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><html><body><a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> <sasy.pa>/Regeneron <regn.o>:Second Dupixent® (Dupilumab) Phase 3 Eosinophilic Esophagitis Trial To Demonstrate Significant Disease Improvements, Underscoring Role Of Type 2 Inflammation In This Complex Disease.Phase 3 Eosinophilic Esophagitis Trial To Demonstrate Significant Disease Improvements.Data Continue To Support Well-Established Safety Profile Of Dupixent.Encouraged That Dupixent, Which Targets Il-4 And Il-13, Was Able To Reduce Inflammation In Esophagus.Look Forward To Continuing Studying Dupixent'S Potential Role In Addressing Underlying Type 2 Inflammation That Can Lead To Eosinophilic Esophagitis.</regn.o></sasy.pa></p><p><blockquote><html><body><a href=\"https://laohu8.com/S/GCVRZ\">赛诺菲</a><sasy.pa>/再生元<regn.o>：第二个Dupixent®（Dupilumab）3期嗜酸性食管炎试验证明了显著的疾病改善，强调了2型炎症在这种复杂疾病中的作用。3期嗜酸性食管炎试验证明疾病有显著改善。数据继续支持Dupixent的良好安全性。令人鼓舞的是，靶向Il-4和Il-13的Dupixent能够减少食道炎症。期待继续研究Dupixent在解决可能导致嗜酸性食管炎的潜在2型炎症方面的潜在作用。</regn.o></sasy.pa></body></html></blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"REGN":"再生元制药公司"},"source_url":"https://www.trkd.thomsonreuters.com","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2178442079","content_text":"Sanofi /Regeneron :Second Dupixent® (Dupilumab) Phase 3 Eosinophilic Esophagitis Trial To Demonstrate Significant Disease Improvements, Underscoring Role Of Type 2 Inflammation In This Complex Disease.Phase 3 Eosinophilic Esophagitis Trial To Demonstrate Significant Disease Improvements.Data Continue To Support Well-Established Safety Profile Of Dupixent.Encouraged That Dupixent, Which Targets Il-4 And Il-13, Was Able To Reduce Inflammation In Esophagus.Look Forward To Continuing Studying Dupixent'S Potential Role In Addressing Underlying Type 2 Inflammation That Can Lead To Eosinophilic Esophagitis.","news_type":1,"symbols_score_info":{"REGN":0.9}},"isVote":1,"tweetType":1,"viewCount":404,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}